Patents by Inventor Martin Seidel

Martin Seidel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250136597
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: October 24, 2024
    Publication date: May 1, 2025
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Publication number: 20250084071
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: January 11, 2023
    Publication date: March 13, 2025
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Publication number: 20240391884
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: July 22, 2024
    Publication date: November 28, 2024
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Patent number: 12152018
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) having formula (I) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: November 26, 2024
    Assignee: IFM Due, Inc.
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Patent number: 12134611
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: November 5, 2024
    Assignee: Novartis AG
    Inventors: Jason Katz, William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman
  • Publication number: 20240308978
    Abstract: This disclosure features chemical entities of Formula I (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: January 7, 2022
    Publication date: September 19, 2024
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Patent number: 12084424
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: September 10, 2024
    Assignee: Novartis AG
    Inventors: Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler
  • Publication number: 20240122903
    Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having: (I) a cancer cell having one or both of (i) decreased TREX1 level and/or activity, and (ii) increased cGAS/STING signaling pathway activity, e.g., as compared to a reference level, and/or (II) an elevated level of cGAMP in a serum or tumor sample obtained from the subject, e.g., as compared to a reference level.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 18, 2024
    Inventors: Gary Glick, Anthony William Opipari, Jr., Hans Martin Seidel
  • Publication number: 20240100017
    Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having decreased SMARCB1 level and/or activity in a tumor sample obtained from the subject as compared to a reference level.
    Type: Application
    Filed: December 21, 2021
    Publication date: March 28, 2024
    Inventors: Gary Glick, Anthony William Opipari, Jr., Hans Martin Seidel
  • Publication number: 20240101556
    Abstract: This disclosure features compounds of Formula I (and their pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said compounds are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: January 7, 2022
    Publication date: March 28, 2024
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Publication number: 20240083879
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: January 7, 2022
    Publication date: March 14, 2024
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Publication number: 20240083895
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: March 1, 2023
    Publication date: March 14, 2024
    Inventors: William R. Roush, Shankar Venkatraman, Gary Glick, Hans Martin Seidel
  • Publication number: 20240076285
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 7, 2024
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Publication number: 20240060982
    Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having decreased ATM level and/or activity in a tumor sample obtained from the subject as compared to a reference level.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 22, 2024
    Inventors: Gary Glick, Anthony William Opipari, Jr., Hans Martin Seidel
  • Publication number: 20240051970
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: December 16, 2021
    Publication date: February 15, 2024
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Publication number: 20240041843
    Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having decreased ATR level and/or activity in a tumor sample obtained from the subject as compared to a reference level.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 8, 2024
    Inventors: Gary Glick, Anthony William Opipari, Jr., Hans Martin Seidel
  • Publication number: 20230416211
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: May 18, 2023
    Publication date: December 28, 2023
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Publication number: 20230365553
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: July 15, 2021
    Publication date: November 16, 2023
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Publication number: 20230271941
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 31, 2023
    Inventors: Shankar Venkatraman, Jason Katz, William R. Roush, Hans Martin Seidel
  • Patent number: 11724992
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: August 15, 2023
    Assignee: Novartis AG
    Inventors: Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler